HighTower Advisors’s Gilead Sciences GILD Stock Holding History

HighTower Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,500	Closed	-$1.26K	–	3773
2025 Q3	$1.26K	Buy	+2,500	New	+$284K	﹤0.01%	3766
2024 Q1	–	Sell	-100	Closed	-$1.88K	–	3772
2023 Q4	$1.88K	Buy	100 +98	+4,900%	+$7.63K	﹤0.01%	3513
2023 Q3	$2.23K	Sell	2 -1	-33%	-$77	﹤0.01%	3463
2023 Q2	$1.09K	Buy	+3	New	+$239	﹤0.01%	3381
2023 Q1	–	Sell	-1	Closed	-$2.02K	–	3520
2022 Q4	$2.02K	Sell	1 -1	-50%	-$79	﹤0.01%	3260
2022 Q3	$1K	Buy	+2	New	+$126	﹤0.01%	3115
2022 Q1	–	Sell	-1	Closed	-$2K	–	3511
2021 Q4	$2K	Sell	1 -99	-99%	-$6.82K	﹤0.01%	3237
2021 Q3	$1K	Buy	+100	New	+$7.03K	﹤0.01%	3125
2014 Q2	–	Sell	-300	Closed	-$1K	–	1640
2014 Q1	$1K	Buy	+300	New	+$23.5K	﹤0.01%	1573

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HighTower Advisors's GILD Position: Q2 2026 in Review

HighTower Advisors increased its Gilead Sciences (GILD) stake by 5.8% in Q2 2026, buying an estimated $11.1M and bringing the position to 1,534,627 shares worth $194M. The position accounts for 0.19% of the portfolio, ranked #115.

HighTower Advisors first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $204M in Q4 2025. 2,279 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

HighTower Advisors held 1,534,627 shares of Gilead Sciences worth $194M as of Q2 2026.
HighTower Advisors bought 84,450 Gilead Sciences shares in Q2 2026, an estimated $11.1M.
Gilead Sciences made up 0.19% of HighTower Advisors's portfolio in Q2 2026, its #115 holding.
HighTower Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
HighTower Advisors's Gilead Sciences position peaked at $204M in Q4 2025.
2,279 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.